In the below chapters, we will discuss recent pre-clinical and clinical efforts to develop IL-2-based immunotherapeutic strategies that target Treg to treat autoimmune conditions characterised by low numbers or reduced suppressive activity of Treg as well as to prevent transplant rejection. The gene discussed is IL2; the disease is Autoimmunity.